Table 1 Demographics of participating patients and children of participating parents in PRISM-IMPACT.

From: Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives

 

Characteristics of children whose parents completed questionnaires (N = 144)

Characteristics of children whose parents completed an interview (N = 43)

Characteristics of patients who completed questionnaires (N = 23)

Age of child at enrolment in PRISM, years

  Mean (SD)

9.1 (5.5)

9.0 (5.7)

14.9 (2.1)

  Range

0–18a

1–17

12–18a

Age of child at diagnosis, years

  Mean (SD)

8.0 (5.5)

7.9 (5.6)

13.0 (2.8)

  Range

0–17

0–17

7–17

Sex, no. (%)

  Female

71 (49.3%)

20 (46.5%)

14 (60.9%)

  Male

73 (50.7%)

23 (53.5%)

9 (39.1%)

Diagnosis, no. (%)

  Central nervous system tumour

57 (28.5%)

16 (37.2%)

5 (21.7%)

  Sarcoma

41 (39.6%)

13 (30.2%)

12 (52.2%)

  Leukaemia/Lymphoma

21 (14.6%)

4 (9.3%)

4 (17.4%)

  Neuroblastoma

14 (9.7%)

4 (9.3%)

0 (0%)

  Otherb

11 (7.6%)

6 (14.0%)

2 (8.7%)

Child relapse prior to PRISM enrolment, no. (%)

  Yes

81 (56.2%)

19 (44.2%)

12 (52.2%)

  No

63 (43.8%)

24 (55.8%)

11 (57.8%)

  1. SD standard deviation, PRISM PRecISion Medicine for Children with Cancer, PRISM-Impact the psychosocial sub-study running alongside the PRISM study, CNS central nervous system.
  2. aThe age restriction was based on the child’s age at the date of consenting to PRISM, while the age summarised in the table is that reported by the parent at baseline. Hence it was possible to include children aged 18 at baseline, if they had their birthday in between PRISM consent and baseline.
  3. bParticipants affected by rare cancers are presented as ‘other’ throughout the manuscript to reduce the chance that they could be identified by their rare diagnosis.
Back to article page